Canaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a $522.00 Price Target


The firm presently has a "buy" rating on the biopharmaceutical company's stock. Canaccord Genuity's price objective suggests a potential upside of 2.61% from the stock's current price.



from Biotech News